These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8719441)

  • 1. Use of combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty treatment.
    Tatò L; Saggese G; Cavallo L; Antoniazzi F; Corrias A; Pasquino AM; Cisternino M
    Horm Res; 1995; 44 Suppl 3():49-54. PubMed ID: 8719441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
    Pucarelli I; Segni M; Ortore M; Arcadi E; Pasquino AM
    J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis.
    Saggese G; Pasquino AM; Bertelloni S; Baroncelli GI; Battini R; Pucarelli I; Segni M; Franchi G
    Acta Paediatr; 1995 Mar; 84(3):299-304. PubMed ID: 7780252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 levels in children with precocious puberty treated with gonadotropin-releasing hormone analog without or in combination with cyproterone acetate.
    Verrotti A; Ferrari M; Sabatino G; Morgese G; Chiarelli F
    Gynecol Endocrinol; 1997 Aug; 11(4):243-50. PubMed ID: 9272420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty.
    Lanes R; Gunczler P
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):197-202. PubMed ID: 9828907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone.
    Cara JF; Kreiter ML; Rosenfield RL
    J Pediatr; 1992 May; 120(5):709-15. PubMed ID: 1533661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group.
    Oostdijk W; Drop SL; Odink RJ; Hümmelink R; Partsch CJ; Sippell WG
    Acta Paediatr Scand Suppl; 1991; 372():39-45; discussion 46. PubMed ID: 1833950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irreversible increase of serum IGF-1 and IGFBP-3 levels in GnRH-dependent precocious puberty of different etiologies: implications for the onset of puberty.
    Belgorosky A; Rivarola MA
    Horm Res; 1998; 49(5):226-32. PubMed ID: 9568807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
    Sklar CA; Rothenberg S; Blumberg D; Oberfield SE; Levine LS; David R
    J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
    Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of sex steroids by a gonadotrophin-releasing hormone agonist increases serum growth hormone-binding protein activity in girls with central idiopathic precocious puberty.
    Kobayashi Y; Murata A; Yasuda T; Minagawa M; Wataki K; Ohnishi H; Niimi H
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):351-5. PubMed ID: 8187298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of precocious puberty with an LH-RH agonist (D-TRP6-LH-RH delayed-release microcapsules)].
    Canlorbe P; Chaussain JL; Lahlou N; Roger M; Toublanc JE; Job JC
    Bull Acad Natl Med; 1988 Nov; 172(8):1091-8. PubMed ID: 2977732
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in growth hormone-binding protein in girls with central precocious puberty treated with a depot preparation of luteinizing hormone-releasing hormone analogue.
    Oliveira SB; Donnadieu M; Chaussain JL
    Horm Res; 1993; 39(1-2):42-6. PubMed ID: 8406338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.